CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
Status:
Not yet recruiting
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
The study is studying the joint contribution and interactions of germline variants and
somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment
(immunotherapy).
Phase:
Phase 2
Details
Lead Sponsor:
Hospital das Clínicas de Ribeirão Preto
Collaborators:
Bristol-Myers Squibb São Paulo Research Foundation (FAPESP)